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Introduction
The killer cell Ig-like receptors (KIRs) 4 belong to a family of structurally related cell membrane receptors that recognize MHC class I molecules. While KIRs are mainly expressed by functional circulating NK cells, they were also found on CD8 + and TCRγδ T lymphocytes, and on a marginal CD4 + T cell population (1) (2) (3) . KIR molecules were classified according to their structure and functional properties into inhibitory and activating forms. Inhibitory receptors (KIR-L) are characterized by a long cytoplasmic tail where are located consensus ITIMs. Once phosphorylated, these latter allow the recruitment of downstream phosphatases, leading to the general shutdown of NK cell effector functions. In contrast,
activating KIRs (KIR-S) encompass a short cytoplasmic tail and mainly use the ITAM-containing adaptor molecule DAP12 to deliver activating signals. For a given receptor, both forms are usually expressed on NK cells and the balance between their respective signaling pathway then determines the ability of NK cells to lyse specific targets (4) .
The expression of NK receptors on effector/memory CD4 + T cells was essentially described under chronic inflammatory conditions. Indeed, it has been reported that clonally expanded CD4 + CD28 null T cells from patients with rheumatoid arthritis (RA) expressed KIRs (5) , with a preferential expression of the activating receptor KIR2DS2/CD158j (6) . In these cells, which do not express DAP12, CD158j was found to selectively activate the DAP12-independent JNK signaling pathway, and was therefore thought to contribute to the T cell-mediated autoimmune disease (7) . Similarly, KIR expression was reported on CD4 + CD28 null T cells from patients with acute coronary syndromes (ACS), with again a preference for the stimulatory variant CD158j (8) . However, DAP12 was frequently transcribed by the ACS patients-derived clones, and CD158j-mediated cytotoxicity was exclusively observed in T-cell clones that expressed both CD158j and DAP12. More recently, we identified KIR3DL2/CD158k as a phenotypic marker of Sézary cells (9) . We further reported the expression of CD158a and CD158b on the circulating CD4 + malignant cells isolated from one Sézary syndrome (SS) patient. In this case, both KIR were found to display a coactivatory function through the recruitment of the JNK-dependent signaling pathway, although the receptors were efficiently expressed under their activating and inhibitory forms at the cell surface (10) . Cells were cultured in RPMI 1640 medium, supplemented with penicillin (100 IU/ml), streptomycin (100 μg/ml), 2 mM L-glutamine (all from Invitrogen, Cergy Pontoise, France), 10% heat-inactivated human serum (Institute of Biotechnologies, Reims, France), and 200 IU/ml rIL2 (a gift of Sanofi-Aventis, Labège, France). Mixed irradiated allogenic PBMC plus 2 µg/ml PHA (Sigma-Aldrich, St Quentin Fallavier, France) were added at the start of the culture and subsequently at 7-to 10-day intervals.
Flow cytometry
Cells were stained with PE-labeled anti-CD158b/j, or FITC-conjugated anti-CD4 or -CD28 mAb using a standard protocol. Alternatively, anti-KIR2DL3 mAb was used followed by goat anti-mouse IgM PElabeled Ig. Appropriate isotype-matched mAbs were used as controls. Cell analyses were performed on an Epics flow cytometer (Beckman Coulter).
Proliferation assays
96-well plates were coated with suboptimal to optimal concentrations of anti-CD3 together with anti- was measured in a liquid scintillation counter (Topcount, Packard Instruments). Results were expressed as the mean of triplicates ± SD.
KIR transcripts analysis
Total mRNA were extracted from 5x10 6 cells using the TRIzol reagent according to the manufacturer's instructions (Invitrogen). Reverse transcription was performed using an oligo-dT (12) (13) (14) (15) (16) (17) (18) primer (Invitrogen) and the Powerscript reverse transcriptase (BD ClonTech, Le Pont de Claix, France). Specific primers for the amplification of KIR2DL2, KIR2DL3 and KIR2DS2 cDNA, as well as amplification conditions, were as described previously (13) . β-actin cDNA amplification was performed in parallel as internal control.
Cell surface biotinylation, immunoprecipitation and immunoblotting
To detect KIR surface expression, cells were biotinylated with sulfo-NHS-LC-biotin prior to lysis (Perbio Sciences, Brebières, France) as previously reported (14) . After washes, cells (2x10 7 per sample) were either left untreated or incubated with 1 mM sodium vanadate and 0.03% H 2 O 2 for 2 min at room temperature. Cells were washed and resuspended in 1% NP40 lysis buffer (20mM Tris-HCl pH7.5, 150mM NaCl, 1% NP40, 1 mM Na vanadate, 10 mM NaF, 1 mM PMSF, 1 μg/ml aprotinin, and 1 μg/ml leupeptin) for 1h at 4°C. After a pre-clearing step on protein A sepharose beads, lysates were subjected to immunoprecipitation with 5 μg of control mIgG1 or anti-CD158b/j GL183 mAb. Immunoprecipitates were collected on protein G sepharose beads, separated by SDS-PAGE, and transferred onto a nitrocellulose membrane. To detect biotinylated proteins, membranes were directly probed with streptavidin-peroxidase and revealed with an ECL system (Perbio Sciences). Alternatively, blots were probed in series with an anti-phosphotyrosine mAb (4G10, Upstate Biotechnology Inc., Lake Placid, NY) and anti-SHP1 antibodies (Cell Signaling Tech., Ozyme, St Quentin en Yvelines, France), or anti-CD3ζ, -appropriated HRP-conjugated secondary antibodies (Jackson Immunoresearch/Beckman Coulter). by densitometry analysis and a relative densitometric intensity (RDI) value was assigned to each band, the RDI of 1 being assigned to the maximal density value obtained under optimal CD3-mediated activation. Fig. 2A) .
Results and Discussion

GL183 mAb triggers activating or inhibitory signals on CD4 + GL183 + T lymphocytes from healthy individuals
However we observed a significant, but opposite, effect of CD158b/j engagement using GL183 mAb on the CD3-mediated proliferation of the cells tested. Thus, a dramatic inhibition of the CD3-induced cell proliferation was detected upon CD158b/j co-ligation on sorted cells corresponding to one set of donors (n=2/6 ; Fig. 2A, group 1) . In contrast, CD158b/j triggering resulted in a significant increase in the CD3-mediated cell growth of the CD4 + GL183 + subpopulation isolated from a second set of individuals (n=4/6; Fig. 2A, group 2) . Thus, depending on the donor, GL183-mediated KIR targeting up-or down-regulated the CD3-mediated proliferation of CD4 + GL183 + T lymphocytes.
Selective expression of CD158b and/or CD158j on CD4 + T lymphocytes
As a result of the high sequence identity existing within the extracellular domain of the inhibitory (KIR-L) and the activating (KIR-S) forms of a given KIR, the commercially available anti-KIR mAb usually recognize both structures. Thus, the generic anti-CD158b/j mAb GL183 efficiently targets To assess which of the three KIR was efficiently expressed at the surface of CD4 + GL183 + T lymphocytes, cells were surface-biotinylated and further subjected to an immunoprecipitation procedure using GL183 mAb. The immunoprecipitates obtained on cells corresponding to individuals from group 1 revealed an exclusive detection of inhibitory molecule(s) presenting an apparent molecular mass of 58 kDa (Fig. 2C, upper panel, group 1) . Further flow cytometry analyses performed with a specific anti-KIR2DL3/CD158b2 mAb (15) showed that this inhibitory receptor was expressed at the cell surface (Fig.   2C, bottom panel) . However, the lack of a specific anti-KIR2DL2 mAb did not allow to establish if the detection of KIR2DL2/CD158b1 transcript also corresponded to protein expression. In contrast, in CD4 + GL183 + T cells corresponding to donors from group 2, only the activating KIR2DS2 receptor was efficiently immunoprecipitated by GL183 mAb, as assessed by the detection of a unique 50 kDa protein (Fig. 2C, group 2) . These data demonstrated that, according to the donor, and despite the simultaneous 
Analysis of CD158b-and CD158j-mediated signaling pathways when expressed in CD4 + T lymphocytes
To definitely demonstrate that the exclusive expression of either KIR2DL2/L3 or KIR2DS2
dictates the KIR function in CD4 + T lymphocytes, CD158b-or CD158j-dependent signaling pathways were analyzed. Inhibitory KIR were shown to exert their activity through the phosphorylation of their intracellular ITIM(s) that subsequently allows their interaction with the phosphatase SHP-1 (17) . We therefore investigated the tyrosine phosphorylation status of CD158b in CD4 + GL183 + T cells isolated from a healthy donor classified in group 1. To this end, cells were left untreated or incubated with vanadate, and subjected to immunoprecipitation using GL183 mAb. Immunoblot analysis of the antiCD158b precipitates with an anti-phosphotyrosine mAb allowed the detection of an activation-dependent phosphorylation of the KIR-L isoforms (Fig. 3A, left panel, group 1) . Consequently, an interaction of the phosphorylated receptor with the phosphatase SHP-1 was evidenced in vanadate-treated cells (Fig. 3A, left panel, group 1). A similar experiment was performed on CD4 + T cells expressing CD158j (Fig. 3A, right panel, group 2). Since stimulatory receptors were shown to initiate intracellular signals through their association with ITAM-containing adaptor molecules, among which DAP10, DAP12, or CD3ζ (17), a possible interaction of CD158j with one of these molecules was investigated. However, neither DAP10 nor DAP12 was found expressed in CD4 + T cells, or detected in CD158j immunoprecipitates (Fig. 3A, right panel). Furthermore, no co-precipitation of CD3ζ with CD158j was observed following cell activation. Thus, it seems that in KIR2DS2-expressing cells, the activating function of the receptor relays on its interaction with an unusual adaptor molecule which identity remains to be defined. Interestingly, a similar observation was done in CD4 + T cell clones isolated from patients with RA or SS. Thus, in these diseases, a KIR2DS2-mediated DAP12-independent cell activation was also described (8, 10) .
In order to ascertain that the exclusive expression of a KIR-L or KIR-S molecule functionally influences CD4 + T cell activation process, the effect of CD158b or CD158j engagement on ERK signaling pathway was investigated. To this aim, CD4 + T cells were stimulated with control mouse IgG1, anti-CD3
or -CD158b/j mAb, or a combination of anti-CD3 and anti-CD158b/j mAb. The corresponding cell lysates were analyzed by Western blot for the detection of phosphorylated ERK (Fig. 3B) . Note that the concentration of anti-CD3 mAb used for activation (1 and 0.2 μg/ml for group 1 and group 2 donors, respectively) was the one previously showed to allow the detection of a maximal effect of KIRengagement on CD3-mediated cell proliferation (see Fig. 2A ). In KIR2DL2/L3-expressing cells, the crosslinking of CD3 with an optimal concentration of mAb (1 μg/ml) together with the KIR allowed the detection of phosphorylated ERK, the phosphorylation level being lower than the one reached upon optimal CD3-mediated activation (Fig. 3B, group 1) . In addition, the use of a suboptimal concentration of anti-CD3 mAb (0.2 μg/ml) on KIR2DS2-positive cells resulted in a discrete ERK activation that is increased in the presence GL183 mAb (Fig. 3B, group 2) . However, in these cells, the triggering of KIR2DS2/CD158j alone was not sufficient by itself to promote ERK activation, as previously reported (18) . Thus, in normal CD4 + T lymphocytes, CD158b or CD158j fulfills a co-receptor function and efficiently modulates the CD3-mediated ERK activation when engaged.
In conclusion, we showed that KIR are expressed as functional co-receptors in CD4 + T lymphocytes from healthy individuals. We further demonstrated that, in this lymphocyte population, the detection of an inhibitory or activating KIR function might correspond to an exclusive and regulated expression of a KIR-L or KIR-S form. In this context, the nature of the delivered KIR-mediated signal would not relay on a commonly proposed model involving the receptors binding affinities to a common ligand (16) , but rather reflects the structural features of the expressed molecule. In our study, the overall Cells were incubated in the presence of control murine IgG1 (mIgG1), anti-CD3 and/or anti-CD158b/j mAb. Following activation, cell lysates were prepared and subjected to gel electrophoresis.
Immunoblotting was performed sequentially using an anti-phospho-Erk1/2 mAb or anti-Erk1/2 antibodies.
The concentrations of the antibodies used for cell activation are given in μg/ml. RDI: relative densitometric intensity. 
